Compare · CYTO vs NVO
CYTO vs NVO
Side-by-side comparison of Altamira Therapeutics Ltd. (CYTO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYTO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $184.33B.
- NVO has hit the wire 8 times in the past 4 weeks while CYTO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for CYTO).
- Company
- Altamira Therapeutics Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $184.33B
- 1M return
- -
- +6.11%
- 1Y return
- -
- -13.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CYTO
- SEC Form 6-K filed by Altamira Therapeutics Ltd.
- Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
- SEC Form SC 13G filed by Altamira Therapeutics Ltd.
- SEC Form 6-K filed by Altamira Therapeutics Ltd.
- Altamira Therapeutics Provides Update on Nasdaq Listing
- Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
- SEC Form 6-K filed by Altamira Therapeutics Ltd.
- Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
- SEC Form 6-K filed by Altamira Therapeutics Ltd.
Latest NVO
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S